RecruitingPhase 1NCT07456878

Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas


Sponsor

Mayo Clinic

Enrollment

5 participants

Start Date

Jan 8, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether a specialized type of PET/MRI scan—using a radioactive tracer called F-18 FET (a marker taken up by active cells)—can find small, hard-to-see tumors in the pituitary gland. Pituitary gland tumors can cause too much production of certain hormones, and sometimes regular MRI scans cannot clearly show where the tumor is located. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with a pituitary condition causing too much cortisol (Cushing's disease), too much growth hormone (acromegaly), or elevated prolactin due to a tumor - Your standard MRI scan was negative or inconclusive for finding the tumor - You are willing to have surgery if the scan finds the tumor, or you are already scheduled for surgery **You may NOT be eligible if...** - You have a contraindication to MRI or PET scans - You have a known allergy to contrast agents used in imaging - You have severe medical conditions that prevent you from lying still for 30–60 minutes - Your MRI scan already clearly identified the tumor Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFET-PET/MRI

Patients will undergo PET/MR scan after intravenous administration of 5 mCi ± 0.5 mCi of Fluoroethyl-L-tyrosine (\[18F\]FET)


Locations(1)

Mayo Clinic

Jacksonville, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07456878


Related Trials